Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

What’s The Future For Medco’s Personalized Medicine Program?

Executive Summary

Express Scripts considers Medco’s personalized medicine program to be complementary to its own expertise in consumer behavior and care coordination, according to presentations on the proposed merger between the two pharmacy benefit managers. But it’s not clear how committed to the program Express Scripts will be.

You may also be interested in...



Express Scripts-Medco Deal Fits Post-Health Reform Realities, But Was Hastened By Contract Losses

Express Scripts’ merger agreement with Medco to form a mega-pharmacy benefits manager may fit into the new realities of the post-health care reform world, but it was also likely hastened by contract losses at Medco.

Tie Goes To The Nominee: Becerra Heads To Senate Floor

Without Republican support, Biden’s HHS nominee couldn’t get a majority in the Finance Committee, but that shouldn’t imperil his bid to become secretary of Health and Human Services.

Topics

UsernamePublicRestriction

Register

LL1133546

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel